Targeting multiple opioid receptors – improved analgesics with reduced side effects?

Classical opioid analgesics, including morphine, mediate all of their desired and undesired effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for treating chronic pain, however, is limited by the development of constipation, respiratory depression, tolerance a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of pharmacology 2018-07, Vol.175 (14), p.2857-2868
Hauptverfasser: Günther, Thomas, Dasgupta, Pooja, Mann, Anika, Miess, Elke, Kliewer, Andrea, Fritzwanker, Sebastian, Steinborn, Ralph, Schulz, Stefan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2868
container_issue 14
container_start_page 2857
container_title British journal of pharmacology
container_volume 175
creator Günther, Thomas
Dasgupta, Pooja
Mann, Anika
Miess, Elke
Kliewer, Andrea
Fritzwanker, Sebastian
Steinborn, Ralph
Schulz, Stefan
description Classical opioid analgesics, including morphine, mediate all of their desired and undesired effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for treating chronic pain, however, is limited by the development of constipation, respiratory depression, tolerance and dependence. Analgesic effects can also be mediated through other members of the opioid receptor family such as the κ‐opioid receptor (κ receptor), δ‐opioid receptor (δ receptor) and the nociceptin/orphanin FQ peptide receptor (NOP receptor). Currently, a new generation of opioid analgesics is being developed that can simultaneously bind with high affinity to multiple opioid receptors. With this new action profile, it is hoped that additional analgesic effects and fewer side effects can be achieved. Recent research is mainly focused on the development of bifunctional μ/NOP receptor agonists, which has already led to novel lead structures such as the spiroindole‐based cebranopadol and a compound class with a piperidin‐4‐yl‐1,3‐dihydroindol‐2‐one backbone (SR16835/AT‐202 and SR14150/AT‐200). In addition, the ornivol BU08028 is an analogue of the clinically well‐established buprenorphine. Moreover, the morphinan‐based nalfurafine exerts its effect with a dominant κ receptor‐component and is therefore utilized in the treatment of pruritus. The very potent dihydroetorphine is a true multi‐receptor opioid ligand in that it binds to μ, κ and δ receptors. The main focus of this review is to assess the paradigm of opioid ligands targeting multiple receptors with a single chemical entity. We reflect on this rationale by discussing the biological actions of particular multi‐opioid receptor ligands, but not on their medicinal chemistry and design. Linked Articles This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc
doi_str_mv 10.1111/bph.13809
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6016677</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1884471811</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4419-90950748d4d4825ef5f0c546cfc4903033662bc97bc0e9cbf8f30b6a068775683</originalsourceid><addsrcrecordid>eNp1kcFO3DAQhi1EVZZtD7wAyhEOgfHGsZ1LK0DQrYRED8DVcpzxrlESp3YC4tZ36BvyJHVZQO0BXyx5Pn2emZ-QPQpHNJ3jelgf0UJCtUVmlAmel4Wk22QGACKnVModshvjHUAqivIj2VnIQkjGFzNye63DCkfXr7Juakc3tJj5wXnXZAENDqMPMXv69Ttz3RD8PTaZ7nW7wuhMzB7cuE5YM5n0Hl2DGVqLZoxfP5EPVrcRP7_cc3JzcX59tswvr759Pzu5zA1jtMorqEoQTDasYXJRoi0tmJJxYw2roICi4HxRm0rUBrAytZW2gJpr4DINwmUxJ1823mGqO2wM9mPQrRqC63R4VF479X-ld2u18veKA-VciCQ4eBEE_3PCOKrORYNtq3v0U1RpeYwJKilN6OEGNcHHGNC-fUNB_c1BpRzUcw6J3f-3rzfydfEJON4AD67Fx_dN6vTHcqP8A_KClBY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1884471811</pqid></control><display><type>article</type><title>Targeting multiple opioid receptors – improved analgesics with reduced side effects?</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Günther, Thomas ; Dasgupta, Pooja ; Mann, Anika ; Miess, Elke ; Kliewer, Andrea ; Fritzwanker, Sebastian ; Steinborn, Ralph ; Schulz, Stefan</creator><creatorcontrib>Günther, Thomas ; Dasgupta, Pooja ; Mann, Anika ; Miess, Elke ; Kliewer, Andrea ; Fritzwanker, Sebastian ; Steinborn, Ralph ; Schulz, Stefan</creatorcontrib><description>Classical opioid analgesics, including morphine, mediate all of their desired and undesired effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for treating chronic pain, however, is limited by the development of constipation, respiratory depression, tolerance and dependence. Analgesic effects can also be mediated through other members of the opioid receptor family such as the κ‐opioid receptor (κ receptor), δ‐opioid receptor (δ receptor) and the nociceptin/orphanin FQ peptide receptor (NOP receptor). Currently, a new generation of opioid analgesics is being developed that can simultaneously bind with high affinity to multiple opioid receptors. With this new action profile, it is hoped that additional analgesic effects and fewer side effects can be achieved. Recent research is mainly focused on the development of bifunctional μ/NOP receptor agonists, which has already led to novel lead structures such as the spiroindole‐based cebranopadol and a compound class with a piperidin‐4‐yl‐1,3‐dihydroindol‐2‐one backbone (SR16835/AT‐202 and SR14150/AT‐200). In addition, the ornivol BU08028 is an analogue of the clinically well‐established buprenorphine. Moreover, the morphinan‐based nalfurafine exerts its effect with a dominant κ receptor‐component and is therefore utilized in the treatment of pruritus. The very potent dihydroetorphine is a true multi‐receptor opioid ligand in that it binds to μ, κ and δ receptors. The main focus of this review is to assess the paradigm of opioid ligands targeting multiple receptors with a single chemical entity. We reflect on this rationale by discussing the biological actions of particular multi‐opioid receptor ligands, but not on their medicinal chemistry and design. Linked Articles This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>ISSN: 1476-5381</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.13809</identifier><identifier>PMID: 28378462</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Analgesics, Opioid - pharmacology ; Analgesics, Opioid - therapeutic use ; Animals ; Humans ; Pain - drug therapy ; Receptors, Opioid - metabolism ; Review ; Themed Section: Review</subject><ispartof>British journal of pharmacology, 2018-07, Vol.175 (14), p.2857-2868</ispartof><rights>2017 The British Pharmacological Society</rights><rights>2017 The British Pharmacological Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4419-90950748d4d4825ef5f0c546cfc4903033662bc97bc0e9cbf8f30b6a068775683</citedby><cites>FETCH-LOGICAL-c4419-90950748d4d4825ef5f0c546cfc4903033662bc97bc0e9cbf8f30b6a068775683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016677/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6016677/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,315,728,781,785,886,1418,1434,27929,27930,45579,45580,46414,46838,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28378462$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Günther, Thomas</creatorcontrib><creatorcontrib>Dasgupta, Pooja</creatorcontrib><creatorcontrib>Mann, Anika</creatorcontrib><creatorcontrib>Miess, Elke</creatorcontrib><creatorcontrib>Kliewer, Andrea</creatorcontrib><creatorcontrib>Fritzwanker, Sebastian</creatorcontrib><creatorcontrib>Steinborn, Ralph</creatorcontrib><creatorcontrib>Schulz, Stefan</creatorcontrib><title>Targeting multiple opioid receptors – improved analgesics with reduced side effects?</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Classical opioid analgesics, including morphine, mediate all of their desired and undesired effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for treating chronic pain, however, is limited by the development of constipation, respiratory depression, tolerance and dependence. Analgesic effects can also be mediated through other members of the opioid receptor family such as the κ‐opioid receptor (κ receptor), δ‐opioid receptor (δ receptor) and the nociceptin/orphanin FQ peptide receptor (NOP receptor). Currently, a new generation of opioid analgesics is being developed that can simultaneously bind with high affinity to multiple opioid receptors. With this new action profile, it is hoped that additional analgesic effects and fewer side effects can be achieved. Recent research is mainly focused on the development of bifunctional μ/NOP receptor agonists, which has already led to novel lead structures such as the spiroindole‐based cebranopadol and a compound class with a piperidin‐4‐yl‐1,3‐dihydroindol‐2‐one backbone (SR16835/AT‐202 and SR14150/AT‐200). In addition, the ornivol BU08028 is an analogue of the clinically well‐established buprenorphine. Moreover, the morphinan‐based nalfurafine exerts its effect with a dominant κ receptor‐component and is therefore utilized in the treatment of pruritus. The very potent dihydroetorphine is a true multi‐receptor opioid ligand in that it binds to μ, κ and δ receptors. The main focus of this review is to assess the paradigm of opioid ligands targeting multiple receptors with a single chemical entity. We reflect on this rationale by discussing the biological actions of particular multi‐opioid receptor ligands, but not on their medicinal chemistry and design. Linked Articles This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc</description><subject>Analgesics, Opioid - pharmacology</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Animals</subject><subject>Humans</subject><subject>Pain - drug therapy</subject><subject>Receptors, Opioid - metabolism</subject><subject>Review</subject><subject>Themed Section: Review</subject><issn>0007-1188</issn><issn>1476-5381</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFO3DAQhi1EVZZtD7wAyhEOgfHGsZ1LK0DQrYRED8DVcpzxrlESp3YC4tZ36BvyJHVZQO0BXyx5Pn2emZ-QPQpHNJ3jelgf0UJCtUVmlAmel4Wk22QGACKnVModshvjHUAqivIj2VnIQkjGFzNye63DCkfXr7Juakc3tJj5wXnXZAENDqMPMXv69Ttz3RD8PTaZ7nW7wuhMzB7cuE5YM5n0Hl2DGVqLZoxfP5EPVrcRP7_cc3JzcX59tswvr759Pzu5zA1jtMorqEoQTDasYXJRoi0tmJJxYw2roICi4HxRm0rUBrAytZW2gJpr4DINwmUxJ1823mGqO2wM9mPQrRqC63R4VF479X-ld2u18veKA-VciCQ4eBEE_3PCOKrORYNtq3v0U1RpeYwJKilN6OEGNcHHGNC-fUNB_c1BpRzUcw6J3f-3rzfydfEJON4AD67Fx_dN6vTHcqP8A_KClBY</recordid><startdate>201807</startdate><enddate>201807</enddate><creator>Günther, Thomas</creator><creator>Dasgupta, Pooja</creator><creator>Mann, Anika</creator><creator>Miess, Elke</creator><creator>Kliewer, Andrea</creator><creator>Fritzwanker, Sebastian</creator><creator>Steinborn, Ralph</creator><creator>Schulz, Stefan</creator><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201807</creationdate><title>Targeting multiple opioid receptors – improved analgesics with reduced side effects?</title><author>Günther, Thomas ; Dasgupta, Pooja ; Mann, Anika ; Miess, Elke ; Kliewer, Andrea ; Fritzwanker, Sebastian ; Steinborn, Ralph ; Schulz, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4419-90950748d4d4825ef5f0c546cfc4903033662bc97bc0e9cbf8f30b6a068775683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Analgesics, Opioid - pharmacology</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Animals</topic><topic>Humans</topic><topic>Pain - drug therapy</topic><topic>Receptors, Opioid - metabolism</topic><topic>Review</topic><topic>Themed Section: Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Günther, Thomas</creatorcontrib><creatorcontrib>Dasgupta, Pooja</creatorcontrib><creatorcontrib>Mann, Anika</creatorcontrib><creatorcontrib>Miess, Elke</creatorcontrib><creatorcontrib>Kliewer, Andrea</creatorcontrib><creatorcontrib>Fritzwanker, Sebastian</creatorcontrib><creatorcontrib>Steinborn, Ralph</creatorcontrib><creatorcontrib>Schulz, Stefan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Günther, Thomas</au><au>Dasgupta, Pooja</au><au>Mann, Anika</au><au>Miess, Elke</au><au>Kliewer, Andrea</au><au>Fritzwanker, Sebastian</au><au>Steinborn, Ralph</au><au>Schulz, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting multiple opioid receptors – improved analgesics with reduced side effects?</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2018-07</date><risdate>2018</risdate><volume>175</volume><issue>14</issue><spage>2857</spage><epage>2868</epage><pages>2857-2868</pages><issn>0007-1188</issn><issn>1476-5381</issn><eissn>1476-5381</eissn><abstract>Classical opioid analgesics, including morphine, mediate all of their desired and undesired effects by specific activation of the μ‐opioid receptor (μ receptor). The use of morphine for treating chronic pain, however, is limited by the development of constipation, respiratory depression, tolerance and dependence. Analgesic effects can also be mediated through other members of the opioid receptor family such as the κ‐opioid receptor (κ receptor), δ‐opioid receptor (δ receptor) and the nociceptin/orphanin FQ peptide receptor (NOP receptor). Currently, a new generation of opioid analgesics is being developed that can simultaneously bind with high affinity to multiple opioid receptors. With this new action profile, it is hoped that additional analgesic effects and fewer side effects can be achieved. Recent research is mainly focused on the development of bifunctional μ/NOP receptor agonists, which has already led to novel lead structures such as the spiroindole‐based cebranopadol and a compound class with a piperidin‐4‐yl‐1,3‐dihydroindol‐2‐one backbone (SR16835/AT‐202 and SR14150/AT‐200). In addition, the ornivol BU08028 is an analogue of the clinically well‐established buprenorphine. Moreover, the morphinan‐based nalfurafine exerts its effect with a dominant κ receptor‐component and is therefore utilized in the treatment of pruritus. The very potent dihydroetorphine is a true multi‐receptor opioid ligand in that it binds to μ, κ and δ receptors. The main focus of this review is to assess the paradigm of opioid ligands targeting multiple receptors with a single chemical entity. We reflect on this rationale by discussing the biological actions of particular multi‐opioid receptor ligands, but not on their medicinal chemistry and design. Linked Articles This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>28378462</pmid><doi>10.1111/bph.13809</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1188
ispartof British journal of pharmacology, 2018-07, Vol.175 (14), p.2857-2868
issn 0007-1188
1476-5381
1476-5381
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6016677
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); PubMed Central; Alma/SFX Local Collection
subjects Analgesics, Opioid - pharmacology
Analgesics, Opioid - therapeutic use
Animals
Humans
Pain - drug therapy
Receptors, Opioid - metabolism
Review
Themed Section: Review
title Targeting multiple opioid receptors – improved analgesics with reduced side effects?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T17%3A56%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20multiple%20opioid%20receptors%20%E2%80%93%20improved%20analgesics%20with%20reduced%20side%20effects?&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=G%C3%BCnther,%20Thomas&rft.date=2018-07&rft.volume=175&rft.issue=14&rft.spage=2857&rft.epage=2868&rft.pages=2857-2868&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.13809&rft_dat=%3Cproquest_pubme%3E1884471811%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1884471811&rft_id=info:pmid/28378462&rfr_iscdi=true